Luisa Maria Knappe, Frederik Anton Verburg, Luca Giovanella, Markus Luster, Damiano Librizzi
Introduction The present study aims to evaluate the clinical diagnostic value of FDG-PET/CT in patients with inflammation of unknown origin. Material and methods We retrospectively analyzed data of 130 patients who presented general inflammatory symptoms and/or elevated level of CRP and underwent FDG-PET/CT for the purpose of identifying unknown foci of inflammation. The accuracy of PET/CT findings was assessed against the standard of eventual clinical diagnosis e.g. results of pathology, microbiology or other imaging methods. Results In 99/130 patients (76 %) a final diagnosis was established, FDG-PET/CT showed a sensitivity and specificity of each 93 %. A decreased pseudocholinesterase is associated with a higher SUVmax value and with a higher CRP value whereas no significant relationship was found between elevated CRP values and the SUVmax, although higher CRP values are associated significantly with a true positive PET/CT result. Conclusion FDG-PET/CT is a highly sensitive, specific and accurate method for the detection of foci of inflammation of unknown origin. The combination of decreased pseudocholinesterase and increased CRP levels may be a useful tool to select patients for FDG PET/CT.
{"title":"Diagnostic value of FDG-PET/CT in the diagnostic work-up of inflammation of unknown origin.","authors":"Luisa Maria Knappe, Frederik Anton Verburg, Luca Giovanella, Markus Luster, Damiano Librizzi","doi":"10.1055/a-1976-1765","DOIUrl":"https://doi.org/10.1055/a-1976-1765","url":null,"abstract":"<p><p>Introduction The present study aims to evaluate the clinical diagnostic value of FDG-PET/CT in patients with inflammation of unknown origin. Material and methods We retrospectively analyzed data of 130 patients who presented general inflammatory symptoms and/or elevated level of CRP and underwent FDG-PET/CT for the purpose of identifying unknown foci of inflammation. The accuracy of PET/CT findings was assessed against the standard of eventual clinical diagnosis e.g. results of pathology, microbiology or other imaging methods. Results In 99/130 patients (76 %) a final diagnosis was established, FDG-PET/CT showed a sensitivity and specificity of each 93 %. A decreased pseudocholinesterase is associated with a higher SUVmax value and with a higher CRP value whereas no significant relationship was found between elevated CRP values and the SUVmax, although higher CRP values are associated significantly with a true positive PET/CT result. Conclusion FDG-PET/CT is a highly sensitive, specific and accurate method for the detection of foci of inflammation of unknown origin. The combination of decreased pseudocholinesterase and increased CRP levels may be a useful tool to select patients for FDG PET/CT.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"27-33"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9220503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal cancer.
Methods: A total of 44 newly diagnosed patients with esophageal cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.
Results: All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.
Conclusion: 68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal cancer.
目的:探讨68Ga-FAPI-04型PET/CT对食管癌早期分期的临床价值。方法:对44例新诊断食管癌患者进行术后病理或临床及影像学随访分析。结果:所有原发病变68Ga-FAPI-04摄取增加，SUVmax为14.92±6.91。共561个淋巴结经手术(507个)或临床及影像学随访(54个)证实，其中92个淋巴结被诊断为转移。68Ga-FAPI-04阳性淋巴结75例，直径约1.06±0.53 cm, SUVmax为8.10±4.71。检测淋巴结转移的敏感性为81.5%，特异性为99.3%，准确性为96.6%，阳性预测值为96.2%，阴性预测值为96.5%。结论:68Ga-FAPI-04型PET/CT对食管癌淋巴结转移有较好的诊断价值。
{"title":"Role of 68Ga-FAPI-04 PET/CT in the Initial Staging of Esophageal Cancer.","authors":"Huipan Liu, Xiao Yang, Zhouxiang You, Zhi Hu, Yue Chen","doi":"10.1055/a-1984-8044","DOIUrl":"https://doi.org/10.1055/a-1984-8044","url":null,"abstract":"<p><strong>Aim: </strong>To investigate the clinical value of 68Ga-FAPI-04 PET/CT for initial staging of esophageal cancer.</p><p><strong>Methods: </strong>A total of 44 newly diagnosed patients with esophageal cancer were included in the analysis on the basis of postoperative pathology or clinical and radiologic follow-up.</p><p><strong>Results: </strong>All primary lesions showed increased 68Ga-FAPI-04 uptake, with an SUVmax of 14.92 ± 6.91. A total of 561 lymph nodes were verified by surgery (507) or clinical and radiologic follow-up (54), of which 92 lymph nodes were diagnosed as showing metastases. Seventy-five lymph nodes with metastases showed positive findings on 68Ga-FAPI-04, with a diameter of about 1.06 ± 0.53 cm and SUVmax of 8.10±4.71. The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for lymph node metastasis detection were 81.5%, 99.3%, 96.6%, 96.2%, and 96.5%, respectively.</p><p><strong>Conclusion: </strong>68Ga-FAPI-04 PET/CT showed good diagnostic performance in detecting lymph node metastases of esophageal cancer.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"62 1","pages":"38-44"},"PeriodicalIF":1.5,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anne Katharina Krebold, Tina Schaller, Madeleine Appenzeller, Martin Schwaiblmair, Malte Kircher, Ralph Alexander Bundschuh, Constantin Lapa, Alexander Dierks
A 55-year-old man with a prior medical history of chronic sinusitis was referred due to progressive dyspnea and weight loss. Computed tomography (CT) of the chest revealed multiple consolidations in both lungs. For further work-up, positron remission tomography/CT (PET/CT) with [18F]fluoro-D-glucose ([18F]FDG) was subsequently performed demonstrating high [18F]FDG uptake in the nasal cavity (SUVmax: 16.9). In addition, intense tracer accumulation in the aforementioned lung lesions (SUVmax: 21.9) was observed (▶ Fig. 1). Biopsies of the nasal septum and the lungs were performed. Pathologic workup revealed acute and chronic inflammation with granulomatous features (▶ Fig. 2), confirmed by the presence of anti-neutrophil cytoplasmic antibodies in serum. A diagnosis of granulomatosis with polyangiitis (GPA) was established, and anti-inflammatory therapy consisting of high dose prednisolone and rituximab was initiated.
{"title":"[18F]FDG PET/CT guided biopsy confirms diagnosis of granulomatosis with polyangiitis.","authors":"Anne Katharina Krebold, Tina Schaller, Madeleine Appenzeller, Martin Schwaiblmair, Malte Kircher, Ralph Alexander Bundschuh, Constantin Lapa, Alexander Dierks","doi":"10.1055/a-1907-4248","DOIUrl":"https://doi.org/10.1055/a-1907-4248","url":null,"abstract":"A 55-year-old man with a prior medical history of chronic sinusitis was referred due to progressive dyspnea and weight loss. Computed tomography (CT) of the chest revealed multiple consolidations in both lungs. For further work-up, positron remission tomography/CT (PET/CT) with [18F]fluoro-D-glucose ([18F]FDG) was subsequently performed demonstrating high [18F]FDG uptake in the nasal cavity (SUVmax: 16.9). In addition, intense tracer accumulation in the aforementioned lung lesions (SUVmax: 21.9) was observed (▶ Fig. 1). Biopsies of the nasal septum and the lungs were performed. Pathologic workup revealed acute and chronic inflammation with granulomatous features (▶ Fig. 2), confirmed by the presence of anti-neutrophil cytoplasmic antibodies in serum. A diagnosis of granulomatosis with polyangiitis (GPA) was established, and anti-inflammatory therapy consisting of high dose prednisolone and rituximab was initiated.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 6","pages":"462-463"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10686482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Friederike Eilsberger, Markus Luster, Damiano Librizzi, Fiona Rodepeter, Katharina Holzer, Andreas Pfestroff
The prostate-specific membrane antigen (PSMA) is established in imaging and treatment of prostate cancer, especially in recurrent disease. PSMA is a membranebound glycoprotein with the function of a glutamic acid releasing carboxypeptidase enzyme, which is biologically expressed by the prostate and among others, proximal renal tubule cells, small intestine, central and peripheral nervous system [1]. Positrone Emission Tomography (PET)/ Computed Tomography (CT) imaging with Gallium (Ga)-68 in prostate cancer has its benefits in demonstrating the extent of the current disease and in preceding possible therapy with radionuclides like Lutetium (Lu)-177 and also the feasibility of intraoperative probe-assisted detection and localization of respective lesions. Numerous immunohistochemical studies have shown that PSMA is also upregulated on the endothelial cells of the neovasculature of a diverse group of other solid tumors. PSMA appears to promote endothelial invasion cell proliferation through its regulation of lytic proteases that can cleave the extracellular matrix [2]. PSMA expression in the neovasculature of tumors was likewise shown for example in renal cell carcinoma, rectal carcinoma, lung cancer, hepatocellular carcinoma, lymphoma, urinary bladder, stomach, small intestine and differentiated thyroid cancer [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]. Heitkötter et al discussed that in thyroid carcinomas, PSMA expression was more common in poorly differentiated species [15]. Poorly differentiated tumors grow rapidly, resulting in intratumoral hypoxemia, in which PSMA supports neovascularization. It is therefore not surprising that several studies have demonstrated an association between high PSMA expression and poorer prognosis and outcome. Haffner et al. were able to demonstrate this association in squamous cell carcinoma of the oral cavity, Jiao et al. in hepatocellular carcinoma and Sollini et al. in differentiated thyroid cancer [16, 17, 18].
{"title":"Medullary Thyroid Carcinoma presenting as an Incidentaloma on Gallium-68-PSMA-PET/CT - Systematic Literature Review and Case Report.","authors":"Friederike Eilsberger, Markus Luster, Damiano Librizzi, Fiona Rodepeter, Katharina Holzer, Andreas Pfestroff","doi":"10.1055/a-1896-0106","DOIUrl":"https://doi.org/10.1055/a-1896-0106","url":null,"abstract":"The prostate-specific membrane antigen (PSMA) is established in imaging and treatment of prostate cancer, especially in recurrent disease. PSMA is a membranebound glycoprotein with the function of a glutamic acid releasing carboxypeptidase enzyme, which is biologically expressed by the prostate and among others, proximal renal tubule cells, small intestine, central and peripheral nervous system [1]. Positrone Emission Tomography (PET)/ Computed Tomography (CT) imaging with Gallium (Ga)-68 in prostate cancer has its benefits in demonstrating the extent of the current disease and in preceding possible therapy with radionuclides like Lutetium (Lu)-177 and also the feasibility of intraoperative probe-assisted detection and localization of respective lesions. Numerous immunohistochemical studies have shown that PSMA is also upregulated on the endothelial cells of the neovasculature of a diverse group of other solid tumors. PSMA appears to promote endothelial invasion cell proliferation through its regulation of lytic proteases that can cleave the extracellular matrix [2]. PSMA expression in the neovasculature of tumors was likewise shown for example in renal cell carcinoma, rectal carcinoma, lung cancer, hepatocellular carcinoma, lymphoma, urinary bladder, stomach, small intestine and differentiated thyroid cancer [3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14]. Heitkötter et al discussed that in thyroid carcinomas, PSMA expression was more common in poorly differentiated species [15]. Poorly differentiated tumors grow rapidly, resulting in intratumoral hypoxemia, in which PSMA supports neovascularization. It is therefore not surprising that several studies have demonstrated an association between high PSMA expression and poorer prognosis and outcome. Haffner et al. were able to demonstrate this association in squamous cell carcinoma of the oral cavity, Jiao et al. in hepatocellular carcinoma and Sollini et al. in differentiated thyroid cancer [16, 17, 18].","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 6","pages":"458-461"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10671602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simone Agnes Schenke, Michael C Kreissl, Michael Grunert, Anja Hach, Sarvar Haghghi, Tatjana Kandror, Eckhard Peppert, Sandra Rosenbaum-Krumme, Verena Ruhlmann, Alexander Stahl, Dieter Wanjura, Konstantin Zaplatnikov, Michael Zimny, Elena Gilman, Ken Herrmann, Rainer Görges
Aim: Thyroid scintigraphy enables the depiction of the functional status of thyroid nodules (TNs) with both, 99mTc-pertechnetate and 123Iodine. The functional status is relevant for diagnostic procedures for the differentiation of benign and malignant TNs. The aim of this study was to examine the current frequencies of hyper-, hypo- and isofunctioning TNs in Germany and to estimate the risk of malignancy with regard to functional status.
Methods: In 11 study centers, a minimum of 100 nodules per center were consecutively enrolled between July 2019 and April 2020. Inclusion criteria were: newly diagnosed nodule, nodule' size of 10 mm or more, thyroid scintigraphy. Exclusion criteria were: completely cystic TNs, patients with prior radioiodine therapy or thyroid surgery. The risk of malignancy was estimated for hyper- and hypofunctioning TNs.
Results: Overall, 849 patients (72 % women) with 1262 TNs were included. Patients' age ranged from 18 to 90 years. Most TNs were hypofunctioning (n=535, 42%) followed by isofunctioning TNs (n=488, 39%) and hyperfunctioning TNs (n=239, 19%). When only TNs with a maximum size of 2 cm or more were considered the rate of hyperfunctioning and hypofunctioning TNs increased (to 27% and 49%) while isofunctioning TNs decreased. Only one of all hyperfunctioning TNs was malignant. In hypofunctioning nodules, the malignancy rate was estimated at 10%.
Conclusion: In Germany, the proportion of hyperfunctioning TNs is approximately 20% and increases in larger TNs to up to 27%. Due to the low risk of malignancy in hyperfunctioning TNs, no further procedures to rule out malignancy are necessary. The risk of malignancy of hypofunctioning TNs is significantly higher. Thus, a thyroid scintigraphy is a useful diagnostic tool in Germany.
{"title":"Distribution of Functional Status of Thyroid Nodules and Malignancy Rates of Hyperfunctioning and Hypofunctioning Thyroid Nodules in Germany.","authors":"Simone Agnes Schenke, Michael C Kreissl, Michael Grunert, Anja Hach, Sarvar Haghghi, Tatjana Kandror, Eckhard Peppert, Sandra Rosenbaum-Krumme, Verena Ruhlmann, Alexander Stahl, Dieter Wanjura, Konstantin Zaplatnikov, Michael Zimny, Elena Gilman, Ken Herrmann, Rainer Görges","doi":"10.1055/a-1856-4052","DOIUrl":"https://doi.org/10.1055/a-1856-4052","url":null,"abstract":"<p><strong>Aim: </strong>Thyroid scintigraphy enables the depiction of the functional status of thyroid nodules (TNs) with both, <sup>99m</sup>Tc-pertechnetate and <sup>123</sup>Iodine. The functional status is relevant for diagnostic procedures for the differentiation of benign and malignant TNs. The aim of this study was to examine the current frequencies of hyper-, hypo- and isofunctioning TNs in Germany and to estimate the risk of malignancy with regard to functional status.</p><p><strong>Methods: </strong>In 11 study centers, a minimum of 100 nodules per center were consecutively enrolled between July 2019 and April 2020. Inclusion criteria were: newly diagnosed nodule, nodule' size of 10 mm or more, thyroid scintigraphy. Exclusion criteria were: completely cystic TNs, patients with prior radioiodine therapy or thyroid surgery. The risk of malignancy was estimated for hyper- and hypofunctioning TNs.</p><p><strong>Results: </strong>Overall, 849 patients (72 % women) with 1262 TNs were included. Patients' age ranged from 18 to 90 years. Most TNs were hypofunctioning (n=535, 42%) followed by isofunctioning TNs (n=488, 39%) and hyperfunctioning TNs (n=239, 19%). When only TNs with a maximum size of 2 cm or more were considered the rate of hyperfunctioning and hypofunctioning TNs increased (to 27% and 49%) while isofunctioning TNs decreased. Only one of all hyperfunctioning TNs was malignant. In hypofunctioning nodules, the malignancy rate was estimated at 10%.</p><p><strong>Conclusion: </strong>In Germany, the proportion of hyperfunctioning TNs is approximately 20% and increases in larger TNs to up to 27%. Due to the low risk of malignancy in hyperfunctioning TNs, no further procedures to rule out malignancy are necessary. The risk of malignancy of hypofunctioning TNs is significantly higher. Thus, a thyroid scintigraphy is a useful diagnostic tool in Germany.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 5","pages":"376-384"},"PeriodicalIF":1.5,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9554216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Tulipan, Angela Jaramillo Guzman, T. Haslerud, Kjartan Foldnes, O. Kvernenes, A. Honoré, N. Brekke, L. Reisæter, M. Biermann
AIMS We observed hitherto unreported layering of radioactivity in the bladder on PET/CT in prostate cancer (PC) when combined with contrast-enhanced CT (CECT). This effect facilitates assessment of the prostate bed in PC. METHODS Among 128 patients imaged with [18F]PSMA-1007, we selected all 8 studies without and 28 studies with CECT. 20 patients also underwent PET/MR. As controls, we chose 20 and 16 males studied with [18F]FDG for extrapelvic disease with and without CECT. Posterior anterior (PA) ratio was calculated as SUVpost/SUVant * 100 % based on maximal standard uptake values (SUV) in 20 mm spheres in the anterior and posterior bladder. Four nuclear physicians scored assessibility of the bladder base on a 3-point Likert scale (3 = optimal, 1 = poor). We acquired serial PET/CT over 4 hours of a flask with layering of 100 ml intravenous contrast agent and 100 ml physiological saline with 40 MBq of [18F]PSMA-1007, while a control flask was shaken at the start of the experiment. RESULTS Layering of tracer was observed in all PET/CT studies with CE-CT, but not in studies without contrast. Median PA ratios were 44 % (interquartile range 33-62) for [18F]PSMA-1007 and 73 % (52-67) for [18F]FDG, respectively. Intravenous contrast improved assessibility scores in PET of the bladder base, but the effect only reached significance in the PET/MR data. In the in vitro data, radioactivity was retained in the aqueous supernatant over the entire experiment whereas there was no separation of phases in the control flask over time. CONCLUSION When performing PET combined with CECT, sedimentation of contrast agent in the bladder leads to upward displacement of radioactivity, enhancing clarity of PET images in the posterior bladder and the prostate bed on both PET/CT and PET/MR.
{"title":"Enhancing PSMA-PET/CT with intravenous contrast: Improved tracer clearance in the prostate bed.","authors":"A. Tulipan, Angela Jaramillo Guzman, T. Haslerud, Kjartan Foldnes, O. Kvernenes, A. Honoré, N. Brekke, L. Reisæter, M. Biermann","doi":"10.1055/a-1821-8112","DOIUrl":"https://doi.org/10.1055/a-1821-8112","url":null,"abstract":"AIMS\u0000We observed hitherto unreported layering of radioactivity in the bladder on PET/CT in prostate cancer (PC) when combined with contrast-enhanced CT (CECT). This effect facilitates assessment of the prostate bed in PC.\u0000\u0000\u0000METHODS\u0000Among 128 patients imaged with [18F]PSMA-1007, we selected all 8 studies without and 28 studies with CECT. 20 patients also underwent PET/MR. As controls, we chose 20 and 16 males studied with [18F]FDG for extrapelvic disease with and without CECT. Posterior anterior (PA) ratio was calculated as SUVpost/SUVant * 100 % based on maximal standard uptake values (SUV) in 20 mm spheres in the anterior and posterior bladder. Four nuclear physicians scored assessibility of the bladder base on a 3-point Likert scale (3 = optimal, 1 = poor). We acquired serial PET/CT over 4 hours of a flask with layering of 100 ml intravenous contrast agent and 100 ml physiological saline with 40 MBq of [18F]PSMA-1007, while a control flask was shaken at the start of the experiment.\u0000\u0000\u0000RESULTS\u0000Layering of tracer was observed in all PET/CT studies with CE-CT, but not in studies without contrast. Median PA ratios were 44 % (interquartile range 33-62) for [18F]PSMA-1007 and 73 % (52-67) for [18F]FDG, respectively. Intravenous contrast improved assessibility scores in PET of the bladder base, but the effect only reached significance in the PET/MR data. In the in vitro data, radioactivity was retained in the aqueous supernatant over the entire experiment whereas there was no separation of phases in the control flask over time.\u0000\u0000\u0000CONCLUSION\u0000When performing PET combined with CECT, sedimentation of contrast agent in the bladder leads to upward displacement of radioactivity, enhancing clarity of PET images in the posterior bladder and the prostate bed on both PET/CT and PET/MR.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"44 1","pages":""},"PeriodicalIF":1.5,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75316039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-01Epub Date: 2022-01-14DOI: 10.1055/a-1659-0010
Steven P Rowe, Andreas Buck, Ralph A Bundschuh, Constantin Lapa, Sebastian E Serfling, Thorsten Derlin, Takahiro Higuchi, Michael A Gorin, Martin G Pomper, Rudolf A Werner
Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, 68Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of 18F-labeled agents. Among others, [18F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [18F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this 18F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [18F]DCFPyL in various clinical settings for men with PC.
{"title":"[18F]DCFPyL PET/CT for Imaging of Prostate Cancer.","authors":"Steven P Rowe, Andreas Buck, Ralph A Bundschuh, Constantin Lapa, Sebastian E Serfling, Thorsten Derlin, Takahiro Higuchi, Michael A Gorin, Martin G Pomper, Rudolf A Werner","doi":"10.1055/a-1659-0010","DOIUrl":"https://doi.org/10.1055/a-1659-0010","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA)-directed positron emission tomography (PET) has gained increasing interest for imaging of men affected by prostate cancer (PC). In recent years, <sup>68</sup>Ga-labeled PSMA compounds have been widely utilized, although there is a trend towards increased utilization of <sup>18</sup>F-labeled agents. Among others, [<sup>18</sup>F]DCFPyL (piflufolastat F 18, PYLARIFY) has been tested in multiple major trials, such as OSPREY and CONDOR, which provided robust evidence on the clinical utility of this compound for staging, restaging, and change in management. Recent explorative prospective trials have also utilized [<sup>18</sup>F]DCFPyL PET/CT for response assessment, e.g., in patients under abiraterone or enzalutamide, rendering this <sup>18</sup>F-labeled PSMA radiotracer as an attractive biomarker for image-guided strategies in men with PC. After recent approval by the U.S. Food and Drug Administration, one may expect more widespread use, not only in the U.S., but also in Europe in the long term. In the present review, we will provide an overview of the current clinical utility of [<sup>18</sup>F]DCFPyL in various clinical settings for men with PC.</p>","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"61 3","pages":"240-246"},"PeriodicalIF":1.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39911564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xue Zhang, H. Wakabayashi, Daiki Kayano, A. Inaki, S. Kinuya
AIM Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals. METHODS I-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells. RESULTS Many studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients. CONCLUSION This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.
{"title":"I-131 metaiodobenzylguanidine therapy is a significant treatment option for pheochromocytoma and paraganglioma.","authors":"Xue Zhang, H. Wakabayashi, Daiki Kayano, A. Inaki, S. Kinuya","doi":"10.1055/a-1759-2050","DOIUrl":"https://doi.org/10.1055/a-1759-2050","url":null,"abstract":"AIM\u0000Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours of chromaffin cells. Several modalities are currently available to treat patients with PPGL. These treatment modalities include surgery, chemotherapy, molecular targeted therapy and radiopharmaceuticals.\u0000\u0000\u0000METHODS\u0000I-131 metaiodobenzylguanidine (mIBG), a classic radiopharmaceutical, can be taken up through specific receptors and sited into many, but not all, PPGL cells.\u0000\u0000\u0000RESULTS\u0000Many studies have investigated the efficacy and toxicity of I-131 mIBG therapy. These studies reported significant results in terms of objective, hormonal and symptomatic responses as well as tolerable toxicities in patients.\u0000\u0000\u0000CONCLUSION\u0000This article reviews the reported experiences of patients who underwent I-131 mIBG therapy for PPGL with a focus on functions and deficiencies of the therapy.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"1 1","pages":"231-239"},"PeriodicalIF":1.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78384216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Greek Mythology and Poetics is the second book in the Myth and Poetics series. My goal, as series editor, is to encourage work that will help integrate literary criticism with the approaches of anthropology and that will pay special attention to problems concerning the nexus of ritual and myth. For such an undertaking, we may look to the comparative testimony of relatively complex societies, such as the Ndembu of Zambia, and also of the very smallest, such as the Yukuna of the Colombian Amazon. 1 Just as important, we must pursue the varied testimonies of the most stratified societies, including those which go under the general heading "Western civilization." It is precisely here that the meaning of myth is the most misleading-and challenging. In a small-scale society myth tends to be viewed as the encoding of that society's concept of truth; at the same time, from the viewpoint of Western civilization, myth has become the opposite of fact, the antithesis of truth. 2 Since the ancient Greek concept of politeiii serves as the foundation for the very word "civilization" and for our concept of Western civilization, more than one of the books in this series will deal primarily with ancient Greece and the ancient Greek city-state, or polis. The testimony of the Greeks is particularly instructive with regard to our central concern, the relationship between ritual and myth. The very word "myth,"
{"title":"Foreword.","authors":"C. Lapa, R. Bundschuh","doi":"10.1055/a-1819-9945","DOIUrl":"https://doi.org/10.1055/a-1819-9945","url":null,"abstract":"Greek Mythology and Poetics is the second book in the Myth and Poetics series. My goal, as series editor, is to encourage work that will help integrate literary criticism with the approaches of anthropology and that will pay special attention to problems concerning the nexus of ritual and myth. For such an undertaking, we may look to the comparative testimony of relatively complex societies, such as the Ndembu of Zambia, and also of the very smallest, such as the Yukuna of the Colombian Amazon. 1 Just as important, we must pursue the varied testimonies of the most stratified societies, including those which go under the general heading \"Western civilization.\" It is precisely here that the meaning of myth is the most misleading-and challenging. In a small-scale society myth tends to be viewed as the encoding of that society's concept of truth; at the same time, from the viewpoint of Western civilization, myth has become the opposite of fact, the antithesis of truth. 2 Since the ancient Greek concept of politeiii serves as the foundation for the very word \"civilization\" and for our concept of Western civilization, more than one of the books in this series will deal primarily with ancient Greece and the ancient Greek city-state, or polis. The testimony of the Greeks is particularly instructive with regard to our central concern, the relationship between ritual and myth. The very word \"myth,\"","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"108 1","pages":"222"},"PeriodicalIF":1.5,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79217391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号